Please login to the form below

CAR-Ts

This page shows the latest CAR-Ts news and features for those working in and with pharma, biotech and healthcare.

Regeneron's bispecific for lymphoma works in CAR-T failures

At the moment, Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) are the CAR-Ts that have been approved to treat DLBCL, with pivotal trials showing that they can ... In this trial, two patients who failed CAR-T

Latest news

Encouraging early data for Amgen’s BiTE therapies

The potential is for the treatments to show superior efficacy to traditional antibodies, while having easier administration and fewer side-effects than CAR-Ts. ... If the BiTE technology is to mount a strong challenge to CAR-Ts, Amgen will want to
Bluebird’s myeloma CAR-T safety ‘could support outpatient use’

prior to the CAR-T and had a minimum of six months’ follow-up after bb2121 dosing. ... Along with CAR-Ts such as Novartis/Poseida’s P-BCMA-01 and Johnson &Johnson’s LCAR-B38M –incudes other therapeutic approaches in development include
Gracell Bio developing faster, cheaper CAR-T production

Gracell confirmed that the tech is not only compatible with the CAR-Ts that are already marketed, but it improves effectiveness of the CAR-Ts in both ALL and NHL. ... The lab modified Novartis' Kymriah and tested the cell therapy in 25 patients, but
Poseida gets Novartis backing for myleoma CAR-T challenger

in single-treatment cures for numerous oncologic indications and orphan genetic diseases, with an initial focus on chimeric antigen receptor T cell (CAR-T) therapies.”. ... The next generation of CAR-Ts are likely to be ‘off the shelf’ allogeneic
CAR-T player Autolus seeks $100m from follow-on financing

approved CAR-T Kymriah (tisagenlecleucel) – which recently generated results in a phase 1/2 trial conducted at University College London. ... in paediatric ALL and diffuse large B cell lymphoma (DLBCL), as well as to continue development of two other

More from news
Approximately 9 fully matching, plus 28 partially matching documents found.

Latest Intelligence

2019: CRISPR and therapeutic gene editing comes of age

TALEN is now being deployed most widely in chimeric antigen receptor T cell (CAR-T) therapies, which generally involve harvesting T cells from patients, modifying them to attack tumour cells by ... Companies like Cellectis and partner Allogene are
Deal Watch October 2018

FITC, which is not naturally present in the body, then becomes the target for CAR‐Ts expressing high affinity for FITC. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

therapies, such as CAR-Ts Kymriah and Yescarta.
Cancer immunotherapy: What's on the horizon?

antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... The CAR-Ts have transformed the treatment
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?

It follows that the next generation of relationship holders, representing very expensive but ultra-personalised medicines like CAR-Ts (which are based on patients’ own cells) will be concierge-like, offering

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director, Healthcare Communications: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director – UK Office: Excellent salary and benefits

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Subscribe to our email news alerts

PMHub

Add my company

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
The evolution of real-world studies: How industry and regulators are using real-world data...